Patients' and Healthcare Professionals' Experiences of Idiopathic Pulmonary Fibrosis Treatment with the Pirfenidone 801mg Tablet Formulation: A Multinational Survey.

Abstract

IntroductionIdiopathic pulmonary fibrosis (IPF) is a progressive, debilitating interstitial lung disease. Two antifibrotics, pirfenidone and nintedanib, are available for IPF treatment. Pirfenidone is available as 267 mg capsules and, more recently, as 267 mg and 801 mg tablets. The aim of this study was to examine the perceived benefits of the 801 mg formulation on patient quality of life (QoL), IPF management and pill burden.MethodsForty-seven patients with IPF and 170 healthcare professionals (HCPs; 150 physicians in France, Germany, Spain and the USA and 20 nurses in the USA) completed online questionnaires comprising 67 and 61 questions, respectively. Eligible patients had experience switching from the 267 mg pirfenidone tablet or capsule formulations to the 801 mg tablet formulation, and eligible HCPs were experienced in managing this switch. Questions included single and multiple responses and scalar questions with responses on a 7-point Likert scale.ResultsPatients received the 267 mg formulation for a median (range) of 6.0 (2.0–40.0) months prior to switching to the 801 mg formulation. Higher percentages of patients reported satisfaction with the 801 mg versus the 267 mg formulation for its convenience (64 vs. 17%) and number of dosage units (70 vs. 2%). More patients reported good emotional well-being on the 801 mg versus the 267 mg formulation (51 vs. 21%), and fewer patients reported missing a dose of pirfenidone (21 vs. 30%). More HCPs perceived high patient adherence with the 801 mg versus the 267 mg formulation (57 vs. 37%). Overall, 33% of physicians had experienced switching patients back to the 267 mg formulation.ConclusionPatients and HCPs consistently favoured the 801 mg formulation across multiple domains, including convenience, patient QoL and adherence. The 801 mg formulation may provide an alternative to the 267 mg formulation in patients established on the recommended daily dose of pirfenidone.Electronic supplementary materialThe online version of this article (10.1007/s41030-020-00111-y) contains supplementary material, which is available to authorized users.